The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults.
The updated recommendation calls for a single vaccine dose for adults ages 50-59 with underlying medical conditions who are at increased risk for severe RSV illness. The CDC’s existing RSV vaccine guidance applies to adults ages 75 and older, as well as high-risk individuals ages 60 to 74.
The committee also recommended a new combination meningococcal vaccine from GSK for all U.S. residents ages 10 and up. The shot protects against five strains of Neisseria meningitidis, eliminating the need for multiple vaccines.
ACIP voted on the new recommendations during an April 15-16 meeting. The guidance is still pending final approval by the CDC and HHS.
